Japan's KM Biologics sees overseas demand for newly approved monkeypox vaccine

TOKYO (Reuters): Japanese pharmaceuticals company KM Biologics Co has already seen overseas interest in its monkeypox vaccine which was recently approved by domestic regulators.

KM Biologics, a unit of candy maker Meiji Holdings Co, has had "several inquiries from overseas" a company official told Reuters on Wednesday (Aug 3), declining to comment on any export plan for the shot.